Anti-PML (Human) mAb

WB - 1 ug/mL (chemiluminescence detection system) IP - It is reported that this clone 1B9 can be used in Immunoprecipitation in the reference number 1. FCM - 10 ug/mL ICC - 1 ug/mL

Acute promyelocytic leukemia (APL) is associated with a t(15;17) translocation that creates the promyelocyte-retinoic acid receptor α (PML-RARα) fusion protein and successfully differentiated by all-trans-retinoic acid (ATRA). PML-RARα consists of all amino acid of RARα except the first 59 amino acids and includes its DNA-binding and ligand-binding domains. PML-RARα contains the functional domains of PML which includes the DNA binding and dimerization property. Thus, the functions of PML and/or retinoid X receptor are sequestrated by PML-RARα in a dominant negative manner. In APL cells, the PML-RARα and PML are immunologically localized as microgranules in the nuclei and cytoplasm, whereas in normal cells, PML is immunologically found as a discrete speckled pattern in nuclei. The ATRA treatment of the APL cells triggers a reorganization of PML to generate normal localization. Anti-PML antibody is a strong tool for the detection of the chromosomal translocation t(15;17) on the APL cells and/or determination of the sensitivity of the APL cells to the ATRA differentiation of hematopoietic cells and apoptosis.

1 mg/mL

100 ug IgG in 100 ul volume of PBS containing 50% glycerol, pH 7.2. Contains no preservative.

Human: 5371 Mouse: 18854

Full-length recombinant human PML

This antibody reacts with PML on Immunocytochemistry, Western blotting and Flow cytometry.

1 year

This antibody was purified from hybridoma (clone 1B9) supernatant using protein A agarose. This hybridoma was established by fusion of mouse myeloma cell P3U1 with Balb/c mouse splenocyte immunized with the recombinant human PML.

PML